NewsDialy
Multiple myeloma, a blood cancer, now has a new oral treatment approved by U.S.
The Food and Drug Administration cleared Zenbexus, made by Bristol Myers Squibb, as the first drug in a new class called CELMoDs and the first drug approved using a more sensitive measure of remission.
On a separate legal track, a federal appeals court reversed a lower court's dismissal of a $6.7 billion suit accusing Bristol Myers of cheating former Celgene shareholders.
How Zenbexus works CELMoDs are a class of drugs that work by redirecting a cell's natural machinery to eliminate cancer-causing proteins.
Keep reading